EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan

Tsubasa Tsutsumi iD, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Hirokazu Takahashi, Miwa Kawanaka, Yoshio Sumida, Michihiro Iwaki iD, Hideki Hayashi, Hidenori Toyoda iD, Satoshi Oeda, Hideyuki Hyogo und 21 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17995 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Tsubasa Tsutsumi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: JSPS KAKENHI, Japan Agency for Medical Research and Development, Fukuoka Clinical Medical Research Award from the Medical Care Education Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A multi‐stakeholder consensus has proposed MASLD (metabolic dysfunction‐associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid‐term mortality of patients with biopsy‐proven MASLD in Japan.

Methods

We enrolled 1349 patients with biopsy‐proven MASLD. The observational period was 8010 person years. We evaluated independent factors associated with mortality in patients with MASLD by Cox regression analysis. We also investigated pathological profiles related to mortality in patients with MASLD using data‐mining analysis.

Results

The prevalence of MASH and stage 3/4 fibrosis was observed in 65.6% and 17.4%, respectively. Forty‐five patients with MASLD died. Of these, liver‐related events were the most common cause at 40% ( n = 18), followed by extrahepatic malignancies at 26.7% ( n = 12). Grade 2/3 lobular inflammation and stage 3/4 fibrosis had a 1.9‐fold and 1.8‐fold risk of mortality, respectively. In the decision‐tree analysis, the profiles with the worst prognosis were characterised by Grade 2/3 hepatic inflammation, along with advanced ballooning (grade 1/2) and fibrosis (stage 3/4). This profile showed a mortality at 8.3%. Furthermore, the random forest analysis identified that hepatic fibrosis and inflammation were the first and second responsible factors for the mid‐term prognosis of patients with MASLD.

Conclusions

In patients with biopsy‐proven MASLD, the prevalence of MASH and advanced fibrosis was approximately 65% and 20%, respectively. The leading cause of mortality was liver‐related events. Hepatic inflammation and fibrosis were significant factors influencing mid‐term mortality. These findings highlight the importance of targeting inflammation and fibrosis in the management of patients with MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisHumansFemaleMaleJapanMiddle AgedAgedBiopsyPrognosisAdultFatty LiverPrevalenceLiverRisk FactorsInflammation

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Liver Center, Saga Medical School, Saga University, Saga, Japan.
  • Department of General Internal Medicine2, Kawasaki Medical Center, Okayama, Japan.
  • Graduate School of Healthcare Management, International University of Healthcare and Welfare, Minato-ku, Japan.

ORCID-Profile: Tsubasa Tsutsumi, Michihiro Iwaki, Hidenori Toyoda, Atsushi Nakajima

Förderung

  • JSPS KAKENHI
  • Japan Agency for Medical Research and Development
  • Fukuoka Clinical Medical Research Award from the Medical Care Education Research Foundation
  • The Japan Strategic Medical Administration Research Center (J-SMARC)

Zitieren

APA

Tsutsumi, T., Kawaguchi, T., Fujii, H., Kamada, Y., Takahashi, H., Kawanaka, M., Sumida, Y., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Morishita, A., Munekage, K., Kawata, K., Sawada, K., Maeshiro, T., Tobita, H., Yoshida, Y., …, & Okanoue, T. (2024). Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17995

Vancouver

Tsutsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, et al. Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17995

BibTeX
@article{Tsutsumi2024,
  author = {Tsutsumi, Tsubasa and Kawaguchi, Takumi and Fujii, Hideki and Kamada, Yoshihiro and Takahashi, Hirokazu and Kawanaka, Miwa and Sumida, Yoshio and Iwaki, Michihiro and Hayashi, Hideki and Toyoda, Hidenori and Oeda, Satoshi and Hyogo, Hideyuki and Morishita, Asahiro and Munekage, Kensuke and Kawata, Kazuhito and Sawada, Koji and Maeshiro, Tatsuji and Tobita, Hiroshi and Yoshida, Yuichi and Naito, Masafumi and Araki, Asuka and Arakaki, Shingo and Noritake, Hidenao and Ono, Masafumi and Masaki, Tsutomu and Yasuda, Satoshi and Tomita, Eiichi and Yoneda, Masato and Tokushige, Akihiro and Ueda, Shinichiro and Aishima, Shinichi and Nakajima, Atsushi and Okanoue, Takeshi},
  title = {Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17995}
}
Kostenlos starten →